Related Experiment Video
Updated: May 25, 2026
08:31
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
Target-based drug discovery, genetic diseases, and biologics
1Biologics Consulting Group, Inc., 19 Sugar Knoll Drive, Devon, PA 19333-1558, USA. ohurko@bcg-usa.com
Neurochemistry International
|February 7, 2012
Summary
Drug discovery shifted to a target-based approach, driven by genomics, combinatorial chemistry, and high-throughput screening. Marshall Nirenberg's foundational work enabled these advances, impacting pharmaceutical applications.
Area of Science:
- Biotechnology
- Pharmacology
- Genomics
Background:
- Drug discovery evolved from empirical methods to a theoretical, target-based strategy.
- This shift was enabled by advances in genomics, ligand production, and screening technologies.
Purpose of the Study:
- To analyze the strategic shift in drug discovery towards a target-based approach.
- To highlight the enabling role of Marshall Nirenberg's scientific contributions.
Main Methods:
- Genomic sequencing for target identification.
- Combinatorial chemistry and monoclonal antibody production for ligand generation.
- High-throughput screening for target-ligand interaction evaluation.
Main Results:
- Genomics facilitated the identification and characterization of drug targets.
- Combinatorial chemistry and monoclonal antibodies enabled efficient ligand production.
- High-throughput screening rapidly evaluated target-ligand interactions.
Conclusions:
- Marshall Nirenberg's work, including the genetic code and hybridoma technology, was crucial for target-based drug discovery.
- This approach has led to both successes and shortcomings in the pharmaceutical industry.
- The implications for therapeutic goals and modalities warrant consideration.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:26Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...